DMAC

8.2602.99%
JK

Julie Krop

Independent Director

Dr. Julie Krop, M.D., is Chief Medical Officer at DiaMedica Therapeutics Inc. since August 06, 2025. She served as Chief Medical Officer of PureTech Health plc since August 2021 until March 31, 2024. Dr. Krop provided independent consulting services as President of JSK Consulting from April 2024 to August 2025. She serves as Independent Director at Aquestive Therapeutics, Inc. since February 10, 2021. Dr. Krop served as the Chief Medical Officer of Freeline Therapeutics Limited and Freeline Therapeutics Holdings plc since April 2020. Dr. Krop served as the Chief Medical Officer of Clinical Development and regulatory affairs at AMAG Pharmaceuticals, Inc from June 2015 to April 2020 and served as its Executive Vice President since December 12, 2017 until March 31, 2020. At AMAG Pharmaceuticals, she oversaw the clinical, medical affairs, program management, pharmacovigilance and regulatory functions. she served as its Senior Vice President of Clinical Development and Regulatory Affairs since June 2015 until December 12, 2017. During her tenure at AMAG, she built a fully integrated development organization and was responsible for overseeing three successful regulatory approvals. Prior to joining AMAG, From 2012 to 2015, Dr. Krop served as the Vice President, Clinical Development for Vertex Pharmaceuticals, Pfizer from April 1999 to February 2001, Millennium from March 2001 to June 2003 and Stryker Regenerative Medicine from September 2006 to October 2012. Dr. Krop served as Vice President for Clinical Development of Peptimmune, Inc. Dr. Krop was responsible for the clinical development of all programs at Peptimmune. Prior to Peptimmune, she was a Director, Clinical Development at Millennium Pharmaceuticals where she led Phase I-II development of MLN-02, a compound in co-development with Genentech for the treatment of Inflammatory Bowel Disease, an autoimmune disease. She has drug development experience across multiple therapeutic areas, including rare and orphan indications, working with clinical teams in the strategic design and execution of development plans and leading the preparation and participation in pre-approval FDA advisory panel presentations and discussions. In addition, she has worked with the FDA and European Medicines Agency (EMEA) to obtain drug approvals in the U.S. and Europe. She also led strategic clinical development programs in the areas of autoimmune and metabolic disorders at Millennium. Prior to Millennium, she served as Associate Director, Clinical Development at Pfizer, where she worked on the Phase III inhaled insulin program. She completed her residency in the Department of Medicine at Georgetown University Hospital. She is board certified in Internal Medicine and completed a Robert Wood Johnson Foundation Clinical Scholar Fellowship as well as an Endocrinology fellowship at the Johns Hopkins University School of Medicine. Dr. Krop received both a B.S. in Biology and an M.D. from Brown University. Dr. Krop received a B.A. from Brown University.

Positions